Skip to main content
QURE
NASDAQ Life Sciences

uniQure Reports Increased Loss, Pursues UK Regulatory Path for AMT-130 Amidst Clinical Setbacks

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$20.89
Mkt Cap
$1.274B
52W Low
$8.73
52W High
$71.5
52W Position info
139% above low
Off High info
71% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73.

Summary

uniQure reported an increased net loss in Q1 2026 but maintained its cash runway, while pursuing a UK regulatory path for AMT-130 and streamlining operations, despite a clinical setback for AMT-191 and discontinuation of AMT-162.


Key Events · Earnings and Guidance · QURE

  • Net Loss Widens

    The company reported a net loss of $53.5 million for Q1 2026, an increase from $43.6 million in the same period last year.

  • New Regulatory Path for AMT-130

    uniQure plans to submit a UK Marketing Authorization Application for its Huntington's disease gene therapy, AMT-130, in Q3 2026, following positive pre-submission feedback from the MHRA.

  • AMT-191 Clinical Dosing Paused

    Additional dosing in the mid- and high-dose cohorts of the Fabry disease program (AMT-191) has been paused due to dose-limiting toxicities (asymptomatic Grade 3 liver enzyme elevations).

  • Operational Streamlining

    The company terminated its HEMGENIX supply obligations with CSL Behring and Genezen, which is expected to amortize a $7.3 million intangible asset and release a $5.8 million purchase commitment liability.


Analysis · QURE · Life Sciences

uniQure's Q1 2026 report reveals a widening net loss and a decrease in total cash and investments, signaling ongoing financial challenges. Despite this, the company reaffirmed its cash runway into the second half of 2029. A significant development is the plan to submit a UK Marketing Authorization Application for AMT-130 in Q3 2026, offering a potential regulatory pathway after the FDA's recommendation for a new trial. However, this positive is tempered by a clinical setback in the Fabry disease program (AMT-191), where dosing was paused due to dose-limiting toxicities, and the discontinuation of the ALS program (AMT-162) which was previously announced. The operational streamlining of HEMGENIX manufacturing obligations is a positive step towards reducing future commitments. Investors should monitor the progress of the UK MAA for AMT-130 and the resolution of the AMT-191 clinical hold, as these will be critical for the company's future.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $20.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $23.81 info
Change: +$1.21 (+5%) info
Market Cap: $1.67B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $23.81 info
Change: +$1.37 (+6%) info
Market Cap: $1.67B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $23.81 info
Change: -$3.85 (-14%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $23.81 info
Change: +$1.81 (+8%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $23.81 info
Change: +$1.61 (+7%) info
Market Cap: $1.67B info